Latest revenue
—
as of 2025-12-31
Latest net income
$-22.2M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ACTU is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $45.0M
- Enterprise value
- $38.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 5.68×
- Dividend yield
- —
- 52-wk high
- —
- 52-wk low
- —
- Beta
- —
- Shares out
- 23.9M
5-year trend
What this company does
Actuate Therapeutics is a clinical-stage biopharma developing elraglusib, a GSK-3β inhibitor, for hard-to-treat cancers including metastatic pancreatic cancer, pediatric tumors, and melanoma. The company generates no product revenue and funds operations through capital raises, with elraglusib as its sole asset licensed from University of Illinois-Chicago and Northwestern. Its Phase 2 trial in metastatic pancreatic cancer hit its primary endpoint in late 2025, showing 10.1 versus 7.2 months median overall survival, a pivotal de-risking milestone.
Generated from ACTU's filing dated 2026-03-26
Key risks
- Single-asset dependency: entire pipeline relies on elraglusib; any safety or regulatory setback would be existential for the company.
- Funding-gated pipeline: Oral Tablet Phase 1, pediatric, melanoma and colorectal programs are explicitly contingent on additional financing not yet secured.
- mPDAC Phase 2 mOS benefit (10.1 vs 7.2 months, p=0.02) is modest; Phase 3 confirmation and FDA approval still required.
Generated from ACTU's filing dated 2026-03-26
Profitability
Return on equity
-280.5%
98.9%Return on assets
-158.4%
45.9%Leverage
Debt / equity
0.77×
99.1%Debt / assets
43.5%
56.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $-4.6M | +29.4% | — |
Q3 2025 2025-09-30 | — | — | $-5.4M | +9.4% | — |
Q2 2025 2025-06-30 | — | — | $-5.9M | +9.5% | — |
Q1 2025 2025-03-31 | — | — | $-6.3M | +23.9% | — |
Q4 2024 2024-12-31 | — | — | $-6.4M | — | — |
Q3 2024 2024-09-30 | — | — | $-6.0M | +5.8% | — |
Q2 2024 2024-06-30 | — | — | $-6.6M | -19.0% | — |
Q1 2024 2024-03-31 | — | — | $-8.3M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ACTU — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$1.5M
Insider selling
$1.6M
Net activity
−$124.0K
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ACTU
Institutional value
$31.3M
Total shares held
11.4M
Distinct holders
36
-9 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BIOS Capital Management, LP | 10.0M | $27.5M | +0 (+0.0%) | No change |
| 2 | BlackRock, Inc. | 427.2K | $1.2M | -4.9K (-1.1%) | Trimmed |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 400.5K | $1.1M | — | New |
| 4 | Connective Capital Management, LLC | 113.3K | $310.3K | — | New |
| 5 | Texas Capital Bank Wealth Management Services Inc | 94.6K | $259.2K | +0 (+0.0%) | No change |
| 6 | VANGUARD FIDUCIARY TRUST CO | 62.6K | $171.5K | — | New |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 55.5K | $152.2K | — | New |
| 8 | Rock Creek Group, LP | 39.3K | $107.6K | +17.5K (+80.4%) | Added |
| 9 | DEUTSCHE BANK AG\ | 36.4K | $99.7K | +27.1K (+291.0%) | Added |
| 10 | SFMG, LLC | 33.0K | $90.4K | +13.0K (+65.0%) | Added |
| 11 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 31.4K | $86.0K | +2.9K (+10.0%) | Added |
| 12 | Gleason Group, Inc. | 19.0K | $52.1K | +0 (+0.0%) | No change |
| 13 | Bank of New York Mellon Corp | 15.4K | $42.2K | +2.9K (+22.7%) | Added |
| 14 | LPL Financial LLC | 13.0K | $35.5K | +0 (+0.0%) | No change |
| 15 | RHUMBLINE ADVISERS | 9.4K | $25.6K | -180 (-1.9%) | Trimmed |
| 16 | NEW YORK STATE COMMON RETIREMENT FUND | 6.2K | $17.0K | +0 (+0.0%) | No change |
| 17 | WELLS FARGO & COMPANY/MN | 5.9K | $16.1K | -14.3K (-70.8%) | Trimmed |
| 18 | Vanguard Global Advisers, LLC | 5.1K | $14.0K | — | New |
| 19 | JPMORGAN CHASE & CO | 3.9K | $8.8K | +68 (+1.8%) | Added |
| 20 | BNP PARIBAS FINANCIAL MARKETS | 2.5K | $6.8K | +100 (+4.2%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
With Phase 2 mPDAC mOS of 10.1 vs 7.2 months, will you pursue accelerated approval or is a Phase 3 trial required, and how is it funded?
- 2
Given multiple programs gated on 'subject to future funding,' what is current cash runway and when do you anticipate needing dilutive financing?
- 3
How does elraglusib's 10.1-month mOS realistically compete with FOLFIRINOX's 11.1-month benchmark in front-line mPDAC commercial positioning?
Refreshed when ACTU files a new report · last from 2026-03-26
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.